GoodRx (NASDAQ:GDRX) shares added ~17% on Thursday after Reuters reported that the drug savings platform, along with a trade group representing pharmacy operators such as Costco (COST), is in talks with the White House about joining the government’s TrumpRx website.
Last week, President Donald Trump unveiled the direct-to-consumer site expected to launch next year, with Pfizer (PFE) agreeing to initially offer four of its brand-name drugs to cash-paying customers at sharp discounts.
Announcing the deal at the Oval Office on Tuesday, Trump said other pharma companies are also expected to join the initiative, which comes under his most-favored-nation (MFN) pricing policy.
GoodRx (NASDAQ:GDRX) CEO Wendy Barnes noted that "if we include the pharma direct programs, we also have to find a way to convey competitive cash pricing at retail pharmacies."
According to Reuters, the National Community Pharmacists Association and the National Association of Chain Drug Stores, which represent pharmacy operators such as Costco (COST), have said they were also in discussions with the Trump administration. CVS Health (CVS), one of the largest pharmacy operators in the U.S., exited the National Association of Chain Drug Stores in 2022.
"As long as drugmakers deliver cost savings for American patients through TrumpRx, how they do so is irrelevant," White House spokesman Kush Desai noted.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.